89bio, Inc/$ETNB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About 89bio, Inc
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Ticker
$ETNB
Sector
Primary listing
Employees
93
Headquarters
Website
89bio, Inc Metrics
BasicAdvanced
$1.2B
-
-$3.41
1.36
-
Price and volume
Market cap
$1.2B
Beta
1.36
52-week high
$11.84
52-week low
$4.16
Average daily volume
1.5M
Financial strength
Current ratio
15.186
Quick ratio
14.167
Long term debt to equity
7.06
Total debt to equity
7.21
Interest coverage (TTM)
-71.06%
Profitability
EBITDA (TTM)
-465.641
Effective tax rate (TTM)
-0.30%
Management effectiveness
Return on assets (TTM)
-49.10%
Return on equity (TTM)
-86.86%
Valuation
Price to book
2.27
Price to tangible book (TTM)
1.92
Price to free cash flow (TTM)
-2.393
Free cash flow yield (TTM)
-41.79%
Free cash flow per share (TTM)
-3.33
Growth
Earnings per share change (TTM)
72.52%
3-year earnings per share growth (CAGR)
-13.05%
What the Analysts think about 89bio, Inc
Analyst ratings (Buy, Hold, Sell) for 89bio, Inc stock.
Bulls say / Bears say
The NASH sector has experienced numerous setbacks, including Akero’s main drug missing its primary trial endpoint and the FDA rejecting Intercept's candidate, highlighting the high risk of clinical failure for pegozafermin. (Reuters)
Allergan’s $1.7 billion purchase of Tobira to enter the NASH market demonstrates intense competition from well-funded companies, raising hurdles for smaller biotechs like 89bio. (Reuters)
Regulatory moves such as Belgium’s decision to ban Novo Nordisk’s Ozempic for weight loss until summer signal potential reimbursement and market access challenges for treatments targeting liver and metabolic conditions, including pegozafermin. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2025.
89bio, Inc Financial Performance
Revenues and expenses
89bio, Inc Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for 89bio, Inc stock?
89bio, Inc (ETNB) has a market cap of $1.2B as of September 17, 2025.
What is the P/E ratio for 89bio, Inc stock?
The price to earnings (P/E) ratio for 89bio, Inc (ETNB) stock is 0 as of September 17, 2025.
Does 89bio, Inc stock pay dividends?
No, 89bio, Inc (ETNB) stock does not pay dividends to its shareholders as of September 17, 2025.
When is the next 89bio, Inc dividend payment date?
89bio, Inc (ETNB) stock does not pay dividends to its shareholders.
What is the beta indicator for 89bio, Inc?
89bio, Inc (ETNB) has a beta rating of 1.36. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.